BioSpace News Archive

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP, 8.4%, 50mEq/50mL (1mEq/mL) Single-Dose Prefilled Syringe.

The findings came from a new Blue Cross Blue Shield Association (BCBSA) report, “Early-Onset Dementia and Alzheimer’s Rates Grow for Younger Americans,” part of the Blue Cross Blue Shield, The Health of America Report® series.

The Leapfrog Group, an independent national health care watchdog organization, released Safety In Numbers: Hospital Performance on Leapfrog’s Surgical Volume Standard Based on Results of the 2019 Leapfrog Hospital Survey.

Launch Ocular Partners, Inc. - Leading Ophthalmology Practice Management Platform in the Midwest

Triple-S Management Corporation (NYSE: GTS), a leading managed care company in Puerto Rico, today announced its fourth quarter 2019 results.

Today, Drug Innovation Ventures at Emory (DRIVE), a nonprofit biotechnology company owned by Emory University, launched a GoFundMe charity campaign to help accelerate testing for its antiviral compound that could potentially be used to treat the new coronavirus associated with the outbreak in China and spreading around the globe.

Ryvu Therapeutics (WSE: RVU), a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced that data from its multiple oncology programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 24 to April 29, 2020, in San Diego, CA.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:

NeuroVasc Technologies, Inc. announced that it has entered into a strategic partnership with the Wego Group that includes $34 million in funding to support the company’s product portfolio development and global clinical trial program.

Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application for a Phase 2 clinical trial of HBM9167, its humanized IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), for the treatment of nasopharyngeal cancer (NPC